Literature DB >> 29205051

Quantitative analysis of imetelstat in plasma with LC-MS/MS using solid-phase or hybridization extraction.

Lieve Dillen1, Luc Sips1, Tony Greway2, Tom Verhaeghe1.   

Abstract

AIM: Imetelstat, a 13-mer oligonucleotide with a lipid tail is being evaluated for treating hematologic myeloid malignancies. This report describes the development of extraction and quantification methods for imetelstat. Methodology & results: Imetelstat was extracted using SPE (rat plasma) or by hybridization using a biotinylated capture probe (human plasma) and was quantified by LC-MS/MS. Calibration curves were established (0.1-50 μg/ml). Stability of imetelstat in plasma was demonstrated. Concentrations of imetelstat extracted using either of the methods and quantified with LC-MS/MS were comparable with a validated ELISA.
CONCLUSION: Two extraction methods (solid phase and hybridization) were developed for quantifying imetelstat in plasma using LC-MS/MS. The hybridization extraction in combination with LC-MS/MS is a novel extraction approach.

Entities:  

Keywords:  SPE; hybridization extraction; oligonucleotide

Mesh:

Substances:

Year:  2017        PMID: 29205051     DOI: 10.4155/bio-2017-0145

Source DB:  PubMed          Journal:  Bioanalysis        ISSN: 1757-6180            Impact factor:   2.681


  2 in total

1.  Delivery of oligonucleotides to bone marrow to modulate ferrochelatase splicing in a mouse model of erythropoietic protoporphyria.

Authors:  François Halloy; Pavithra S Iyer; Paulina Ćwiek; Alice Ghidini; Jasmin Barman-Aksözen; Nicole Wildner-Verhey van Wijk; Alexandre P A Theocharides; Elisabeth I Minder; Xiaoye Schneider-Yin; Daniel Schümperli; Jonathan Hall
Journal:  Nucleic Acids Res       Date:  2020-05-21       Impact factor: 16.971

Review 2.  Oligonucleotides Isolation and Separation-A Review on Adsorbent Selection.

Authors:  Sylwia Studzińska; Łukasz Nuckowski; Bogusław Buszewski
Journal:  Int J Mol Sci       Date:  2022-08-23       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.